BR112018014585A2 - receptores de antígeno quiméricos que direcionam o receptor do fator de crescimento epidérmico variante iii - Google Patents

receptores de antígeno quiméricos que direcionam o receptor do fator de crescimento epidérmico variante iii

Info

Publication number
BR112018014585A2
BR112018014585A2 BR112018014585A BR112018014585A BR112018014585A2 BR 112018014585 A2 BR112018014585 A2 BR 112018014585A2 BR 112018014585 A BR112018014585 A BR 112018014585A BR 112018014585 A BR112018014585 A BR 112018014585A BR 112018014585 A2 BR112018014585 A2 BR 112018014585A2
Authority
BR
Brazil
Prior art keywords
growth factor
factor receptor
epidermal growth
chimeric antigen
antigen receptors
Prior art date
Application number
BR112018014585A
Other languages
English (en)
Inventor
Ching Chou Joyce
Smith Julianne
Brunnhilde Dusseaux Mathilde
Kwan Wong Oi
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of BR112018014585A2 publication Critical patent/BR112018014585A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Abstract

a presente invenção refere-se a receptores de antígeno quimérico (cars) que se ligam especificamente ao egfrviii (receptor do fator de crescimento epidérmico variante iii). a invenção refere-se ainda às células imunes planejadas compreendendo tais cars, ácidos nucleicos de codificação do car, e métodos para a sua produção, células imunes planejadas e ácidos nucleicos. a invenção refere-se ainda aos métodos terapêuticos para uso destes car e células imunes planejadas para o tratamento de patologias mediadas pelo egfrviii, incluindo cânceres tais como glioblastoma.
BR112018014585A 2016-01-21 2017-01-10 receptores de antígeno quiméricos que direcionam o receptor do fator de crescimento epidérmico variante iii BR112018014585A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662281533P 2016-01-21 2016-01-21
US201662431758P 2016-12-08 2016-12-08
PCT/IB2017/050108 WO2017125830A1 (en) 2016-01-21 2017-01-10 Chimeric antigen receptors targeting epidermal growth factor receptor variant iii

Publications (1)

Publication Number Publication Date
BR112018014585A2 true BR112018014585A2 (pt) 2018-12-11

Family

ID=57868301

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018014585A BR112018014585A2 (pt) 2016-01-21 2017-01-10 receptores de antígeno quiméricos que direcionam o receptor do fator de crescimento epidérmico variante iii

Country Status (22)

Country Link
US (3) US10259876B2 (pt)
EP (1) EP3405481B1 (pt)
JP (2) JP6823659B2 (pt)
KR (1) KR102479606B1 (pt)
CN (1) CN108699124A (pt)
AU (1) AU2017208834B2 (pt)
BR (1) BR112018014585A2 (pt)
CA (1) CA2954014A1 (pt)
DK (1) DK3405481T3 (pt)
EA (1) EA201891641A1 (pt)
ES (1) ES2942362T3 (pt)
IL (1) IL260666B2 (pt)
MX (1) MX2018008978A (pt)
MY (1) MY192474A (pt)
NZ (1) NZ744821A (pt)
PH (1) PH12018501473A1 (pt)
RU (1) RU2751662C2 (pt)
SA (1) SA518392058B1 (pt)
SG (2) SG11201805872SA (pt)
TW (2) TWI755547B (pt)
UA (1) UA125252C2 (pt)
WO (1) WO2017125830A1 (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017075537A1 (en) 2015-10-30 2017-05-04 Aleta Biotherapeutics Inc. Compositions and methods for treatment of cancer
CA3003144A1 (en) 2015-10-30 2017-05-04 Aleta Biotherapeutics Inc. Compositions and methods for tumor transduction
BR112018014585A2 (pt) * 2016-01-21 2018-12-11 Pfizer receptores de antígeno quiméricos que direcionam o receptor do fator de crescimento epidérmico variante iii
ES2904593T3 (es) 2016-01-21 2022-04-05 Pfizer Anticuerpos monoespecíficos y biespecíficos para la variante III del receptor del factor de crecimiento epidérmico y CD3 y sus usos
JP2020511462A (ja) 2016-12-03 2020-04-16 ジュノー セラピューティクス インコーポレイテッド キナーゼ阻害剤との組み合わせで治療用ｔ細胞を使用するための方法および組成物
MX2019014268A (es) 2017-06-02 2020-08-03 Juno Therapeutics Inc Artículos de manufactura y métodos para tratamiento usando terapia celular adoptiva.
WO2019195586A1 (en) * 2018-04-06 2019-10-10 The Regents Of The University Of California Methods of treating egfrviii expressing glioblastomas
EP3827075A4 (en) * 2018-07-26 2022-08-03 Nanjing Legend Biotech Co., Ltd. NEF-CONTAINING T LYMPHOCYTES AND THEIR PRODUCTION METHODS
CN109265561B (zh) * 2018-09-25 2021-05-25 山东兴瑞生物科技有限公司 抗EGFRvⅢ安全型嵌合抗原受体、其制备方法、利用其修饰的NK细胞及应用
US20220033848A1 (en) * 2018-11-19 2022-02-03 Board Of Regents, The University Of Texas System A modular, polycistronic vector for car and tcr transduction
TW202039544A (zh) * 2018-12-01 2020-11-01 美商艾洛基因醫療公司 靶定ｂ細胞成熟抗原之嵌合抗原受體及其使用之方法
CN113621062A (zh) * 2018-12-21 2021-11-09 豪夫迈·罗氏有限公司 与cd3结合的抗体
CN111454358A (zh) * 2019-01-18 2020-07-28 四川科伦博泰生物医药股份有限公司 一种嵌合抗原受体及其应用
WO2020190771A1 (en) * 2019-03-15 2020-09-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric adaptor and kinase signaling proteins and their use in immunotherapy
EP3994173A1 (en) * 2019-07-02 2022-05-11 The United States of America, as represented by the Secretary, Department of Health and Human Services Monoclonal antibodies that bind egfrviii and their use
US20220288118A1 (en) * 2019-07-31 2022-09-15 Forty Seven, Inc. Depletion regimes for engineered t-cell or nk-cell therapy
CN111019959B (zh) * 2019-12-30 2022-09-13 北京立康生命科技有限公司 一种体外转录mRNA的核苷酸分子、呈递细胞及应用
WO2021150936A1 (en) * 2020-01-22 2021-07-29 City Of Hope Oncolytic virus compositions including il-15 complex and methods for the treatment of cancer
EP4263590A1 (en) 2020-12-21 2023-10-25 Allogene Therapeutics, Inc. Protease-activating cd45-gate car
EP4284918A1 (en) 2021-01-29 2023-12-06 Allogene Therapeutics, Inc. Knockdown or knockout of one or more of tap2, nlrc5, beta2m, trac, rfx5, rfxap and rfxank to mitigate t cell recognition of allogeneic cell products
WO2024026445A1 (en) 2022-07-29 2024-02-01 Allogene Therapeutics Inc. Engineered cells with reduced gene expression to mitigate immune cell recognition
WO2024027835A1 (zh) * 2022-08-05 2024-02-08 北京鼎成肽源生物技术有限公司 靶向EGFRvIII的抗体及其在细胞免疫治疗的应用
CN116284435A (zh) * 2022-09-19 2023-06-23 卡瑞济(北京)生命科技有限公司 EGFRvIII嵌合抗原受体及其用途

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
GB8611832D0 (en) 1986-05-15 1986-06-25 Holland I B Polypeptide
US5037743A (en) 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
CA2137558A1 (en) 1992-07-17 1994-02-03 Wayne A. Marasco Method of intracellular binding of target molecules
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
ATE373078T1 (de) 2000-02-24 2007-09-15 Xcyte Therapies Inc Gleichzeitige stimulation und konzentration von zellen
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
EP1266009B1 (en) * 2000-02-25 2008-12-31 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES ANTI-EGFRvIII SCFVS WITH IMPROVED CYTOTOXICITY AND YIELD, IMMUNOTOXINS BASED THEREON, AND METHODS OF USE THEREOF
WO2008045437A2 (en) 2006-10-09 2008-04-17 The General Hospital Corporation Chimeric t-cell receptors and t-cells targeting egfrviii on tumors
AU2011319725A1 (en) 2010-10-27 2013-05-30 Cellectis Method for increasing the efficiency of double-strand break-induced mutagenesis
US9249217B2 (en) 2010-12-03 2016-02-02 Secretary, DHHS Bispecific EGFRvIII x CD3 antibody engaging molecules
JP5947311B2 (ja) 2010-12-09 2016-07-06 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 癌を治療するためのキメラ抗原受容体改変ｔ細胞の使用
PL2694549T3 (pl) * 2011-04-08 2019-01-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeryczne receptory antygenowe anty-wariant III receptora czynnika wzrostu naskórka i ich zastosowanie do leczenia raka
GB201206559D0 (en) 2012-04-13 2012-05-30 Ucl Business Plc Polypeptide
US20150017136A1 (en) 2013-07-15 2015-01-15 Cellectis Methods for engineering allogeneic and highly active t cell for immunotherapy
CA2876133C (en) 2012-06-07 2017-06-06 Duke University Human bispecific egfrviii antibody engaging molecules
JP2015524255A (ja) * 2012-07-13 2015-08-24 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 二重特異性抗体を共導入することによってｃａｒｔ細胞の活性を強化する方法
KR102141259B1 (ko) 2012-09-04 2020-08-05 셀렉티스 멀티―체인 키메라 항원 수용체 및 그것의 용도들
AU2013204922B2 (en) * 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
DK2958943T3 (da) * 2013-02-20 2019-12-09 Univ Pennsylvania Behandling af cancer ved anvendelse af humaniseret anti-EGFRvIII kimær antigenreceptor
EP3721902A1 (en) 2013-03-14 2020-10-14 The Scripps Research Institute Targeting agent antibody conjugates and uses thereof
CA2912375C (en) 2013-05-13 2023-03-14 Cellectis Methods for engineering highly active t cell for immunotherapy
AU2014267436B2 (en) 2013-05-13 2019-07-04 Cellectis CD19 specific chimeric antigen receptor and uses thereof
DK3004337T3 (da) 2013-05-29 2017-11-13 Cellectis Fremgangsmåde til konstruktion af T-celler til immunoterapi ved brug af RNA-guidet Cas nuklease-system
TR201904121T4 (tr) 2013-07-09 2019-04-22 The Government Of The United States As Represented By The Secretary Of The Dept Of Health And Human İnsan bispesifik egfrviii antikoru birleştirme molekülleri.
DK3030581T3 (da) 2013-08-07 2021-04-12 Affimed Gmbh Antistofbindingssteder, der er specifikke for egfrviii
JP2017504601A (ja) * 2013-12-20 2017-02-09 セレクティスＣｅｌｌｅｃｔｉｓ 免疫療法のためにマルチインプットシグナル感受性ｔ細胞を操作する方法
CN107074973A (zh) 2014-07-29 2017-08-18 辉瑞大药厂 用于癌症免疫疗法的EGFRvIII特异性嵌合抗原受体
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
BR112018014585A2 (pt) 2016-01-21 2018-12-11 Pfizer receptores de antígeno quiméricos que direcionam o receptor do fator de crescimento epidérmico variante iii
ES2904593T3 (es) 2016-01-21 2022-04-05 Pfizer Anticuerpos monoespecíficos y biespecíficos para la variante III del receptor del factor de crecimiento epidérmico y CD3 y sus usos

Also Published As

Publication number Publication date
IL260666B (en) 2022-10-01
US20190144550A1 (en) 2019-05-16
EA201891641A1 (ru) 2019-01-31
PH12018501473A1 (en) 2019-03-11
SG10202111458RA (en) 2021-11-29
RU2018130088A3 (pt) 2020-07-29
US10259876B2 (en) 2019-04-16
JP6823659B2 (ja) 2021-02-03
US20220227874A1 (en) 2022-07-21
AU2017208834B2 (en) 2021-09-02
MX2018008978A (es) 2019-01-10
TWI634125B (zh) 2018-09-01
SA518392058B1 (ar) 2023-02-12
US20170210811A1 (en) 2017-07-27
AU2017208834A1 (en) 2018-08-09
JP7198797B2 (ja) 2023-01-04
ES2942362T3 (es) 2023-05-31
TW201920237A (zh) 2019-06-01
SG11201805872SA (en) 2018-08-30
IL260666A (en) 2018-09-20
TW201734038A (zh) 2017-10-01
RU2018130088A (ru) 2020-02-25
EP3405481A1 (en) 2018-11-28
NZ744821A (en) 2023-06-30
IL260666B2 (en) 2023-02-01
CN108699124A (zh) 2018-10-23
JP2021036873A (ja) 2021-03-11
TWI755547B (zh) 2022-02-21
US11267892B2 (en) 2022-03-08
KR20180099890A (ko) 2018-09-05
DK3405481T3 (da) 2023-04-17
UA125252C2 (uk) 2022-02-09
EP3405481B1 (en) 2023-01-18
WO2017125830A1 (en) 2017-07-27
MY192474A (en) 2022-08-23
KR102479606B1 (ko) 2022-12-21
RU2751662C2 (ru) 2021-07-15
CA2954014A1 (en) 2017-07-21
JP2019506394A (ja) 2019-03-07

Similar Documents

Publication Publication Date Title
BR112018014585A2 (pt) receptores de antígeno quiméricos que direcionam o receptor do fator de crescimento epidérmico variante iii
CO2017010502A2 (es) Receptores del antígeno quimérico dirigidos al antígeno de maduración de células b
MX2021003704A (es) Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales.
PH12017502019A1 (en) Heterodimeric antibodies that bind cd3 and tumor antigens
PH12015502293A1 (en) Bispecific antibodies specific for fap and dr5, antibodies specific for dr5 and methods of use
NZ762843A (en) Anti-egfr antibodies and antibody drug conjugates
PH12019501357A1 (en) Anti-ox40 antibodies and their uses
PH12017500890A1 (en) Antibody drug conjugates
MX2017005814A (es) Inmunoglobulinas hetero-dimericas de redireccionamiento de celulas t cd3/cd38 y sus metodos de produccion.
MX2015012122A (es) Conjugados de anticuerpo-farmaco y los anticuerpos correspondientes.
MX2017001403A (es) Constructo de anticuerpo de cadena individual biespecifico con distribucion mejorada de tejido.
PH12017500002A1 (en) Anti-cdh6 antibody drug conjugates
PE20210107A1 (es) Anticuerpos anti-cd3 y metodos de uso
PH12016502061A1 (en) Novel antii-rnf43 antibodies and methods of use
MX2017011344A (es) Anticuerpos diseñados de sitio específico y métodos de uso.
MY184189A (en) Methods of treating nail and scalp psoriasis
MX2022000242A (es) Anticuerpos contra ticagrelor y metodos de uso.
ES2721935T3 (es) Anticuerpos anti-BAG3 para uso terapéutico
MX2016012620A (es) Anticuerpos contra atigeno de plaqueta 1a humano (hpa-1a).
SA516370731B1 (ar) عملية لتحضير جزء وجبة تباع الشمس عالية البروتين
MX2016014726A (es) Proteinas de union al antigeno her1 que se unen a la beta-horquilla de her1.
AR107431A1 (es) Anticuerpos específicos contra la variante iii del receptor del factor de crecimiento epidérmico y sus usos

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]